section name header

Basics

Description
Epidemiology

Incidence

  • US: 3–14 cases per 100,000 persons (1)
  • Bimodal distribution with diagnosis peaking in the teens 20s then in the 50–70s (1)

Prevalence

  • US: 26–200 per 100,000 persons (2)
  • Females have a slightly higher prevalence (2)
  • More frequent in people who have a first-order relative with the disease (2).

Morbidity

  • There is no cure for Crohn's disease patients suffer from flare-ups that can cause significant discomfort weight loss.
  • If medical therapy is not effective, surgical resection of inflamed bowel is the treatment of choice.

Mortality

Mortality rate is low, but there is an increased rate of small bowel colorectal cancers.

Etiology/Risk Factors
Physiology/Pathophysiology
Anesthetic GOALS/GUIDING Principles

Diagnosis

Symptoms

Exacerbations consist of diarrhea (increased frequency, fluidity, daily volume of stool), abdominal bloating, distention, discomfort, cramps particularly after meals, acute pain in the lower right abdomen, hyperactive bowel sounds, infection, blood in stool (or greasy, foul-smelling, fatty stool), nausea vomiting, weight loss, dry mouth.

History

  • Acute flare versus chronic condition
  • History of anti-inflammatory, antidiarrheal, antidepressant use
  • Severity, especially with regard to fluid electrolyte status
  • Current hyperalimentation therapy
  • Diabetes hypertension from chronic steroid use

Signs/Physical Exam

  • Signs of dehydration—decreased skin turgor, decreased capillary refill, decreased urinary output, tachycardia, hypotension, etc.
  • Signs of electrolyte abnormalities—ECG changes, muscle weakness, etc.
  • Rectocutaneous fistulas
  • Malnutrition vitamin deficiencies
  • Painful lower extremity swelling may indicate deep venous thrombosis (increased risk); shortness of breath or hypoxia should warrant consideration of a pulmonary embolism.
Treatment History

Surgical resection of affected portions of the intestines

Medications
Diagnostic Tests & Interpretation

Labs/Studies

  • CBC to assess for anemia hemoconcentration
  • Complete metabolic panel (BUN/Cr ratio of 20:1 may indicate dehydration; low bicarbonate values may indicate acidosis due to dehydration or infection)
  • Coagulation studies if liver disease is present
  • EKG may be considered for electrolyte abnormalities or patient specific indications
  • Type screen or type cross.
CONCOMITANT ORGAN DYSFUNCTION

Extraintestinal manifestations include:

Circumstances to delay/Conditions
Classifications

Treatment

PREOPERATIVE PREPARATION

Premedications

  • Anxiolysis as needed
  • Stress dose steroids should be considered if the patient has been treated for more than 2 weeks within the past 6–12 months to avoid manifestations of adrenal insufficiency. Steroids with glucocorticoid mineralocorticoid activity should be administered (e.g., hydrocortisone).
INTRAOPERATIVE CARE

Choice of Anesthesia

  • Depends on type of surgery, patient wishes, surgeon's preferences.
  • Neuraxial placement may be contraindicated if coagulation studies are abnormal.
  • Hyperalimentation is usually continued in the intraoperative period. If stopped, hypoglycemia may result.

Monitors

  • Stard ASA monitors
  • Foley catheter in long cases, patients with suspected hypovolemia, or anticipated large fluid shifts
  • Foley catheter may be indicated for long cases, anticipated large fluid shifts, or hypovolemic patients.
  • Consider central venous catheter with central venous pressure for fluid management, as appropriate.

Induction/Airway Management

  • In hypovolemic patients consider adequate preoperative fluid hydration prior to induction.
  • Etomidate or ketamine can be useful in hypovolemic patients; have vasopressors available.
  • In anemic patients, consider having blood available or transfuse prior to induction.
  • To avoid additional oral trauma, perform gentle laryngoscopy intubation.
  • If aphthous ulcers are present, may avoid leaving a bite block in the mouth.

Maintenance

  • Muscle relaxation can aid surgical exposure closure of abdominal fascia for bowel surgery
  • Fluid management: Replace deficits with crystalloid factor in insensible losses. Patients are at risk for significant third-spacing bowel edema, especially due to low colloid oncotic pressures. This can make closure of abdominal incisions more difficult.
  • Low albumin levels due to malnutrition: Adjust medication doses appropriately, particularly with highly protein-bound drugs. Unbound, free drug is pharmacologically active, is also available for metabolism. Thus, consider smaller boluses more frequent dosing. Additionally, hypoalbuminemia may result in increased total body water volume of distribution.
  • Consider avoiding nitrous oxide for bowel surgery as it can cause the bowel to exp make fascial closure more difficult.
  • Chronic steroid use may result in diabetes; intraoperative glucose management may require insulin administration.
  • Intractable intraoperative hypotension may be due to adrenal insufficiency; treat with stress dose steroids.
  • Eye protection to avoid worsening ocular manifestations
  • Skin may be thin or easily breached from long-term steroid use; caution with positioning tape for IV sites, endotracheal tube (ETT), eyes.

Extubation/Emergence

Reversal of nondepolarizing muscle relaxants can help minimize weakness as patients often have underlying weakness due to malnutrition electrolyte disturbances.

Follow-Up

Bed Acuity

Telemetry if the patient has severe electrolyte derangements.

Medications/Lab Studies/Consults
Complications

Hyperalimentation can result in hypo/hyperglycemia, hyperchloremic metabolic acidosis, fluid overload, electrolyte abnormalities, renal hepatic dysfunction

References

  1. Loftus EV Jr . Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, environmental influences. Gastroenterology. 2004;126(6):15041517.
  2. Kappelman MD , Rifas-Shiman SL , Kleinman K , et al. The prevalence geographic distribution of Crohn's disease ulcerative colitis in the United States. Clin Gastroenterol Hepatol. 2007;5(12):14241429.
  3. Abraham C , Cho JH. Inflammatory bowel disease. N Eng J Med. 2009:361(21):20662078.
  4. Baumgart DC , Sborn WJ. Inflammatory bowel disease: Clinical aspects established evolving therapies. The Lancet. 2007;369(9573):16411657.

Additional Reading

See Also (Topic, Algorithm, Electronic Media Element)

Codes

ICD9
ICD10

Clinical Pearls

Author(s)

rea Parsons , MD